Apeikon Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $179K

  • Investors
  • 10

Apeikon Therapeutics General Information

Description

Developer of activatable nanoparticles designed for targeted drug delivery in hard-to-treat tumors. The company serves clinicians who need to treat deep-seated, inaccessible tumors, improving efficacy, avoiding adverse effects and multiple hospital visits, enabling patients to get proper treatment by using magnetic resonance imaging-directed remotely activatable therapeutics in tumors.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 71-75 Shelton Street
  • Covent Garden
  • London WC2H 9JQ
  • England, United Kingdom
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Drug Discovery
Corporate Office
  • 71-75 Shelton Street
  • Covent Garden
  • London WC2H 9JQ
  • England, United Kingdom

Apeikon Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apeikon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Early Stage VC 03-Apr-2023 $179K Completed Generating Revenue
11. Accelerator/Incubator 23-Feb-2023 Completed Generating Revenue
10. Grant 10-Feb-2023 Completed Generating Revenue
9. Accelerator/Incubator 01-Jan-2023 Completed Generating Revenue
8. Accelerator/Incubator 30-Sep-2022 Completed Generating Revenue
7. Grant 01-Jun-2022 Completed Generating Revenue
6. Grant 06-Jan-2022 Completed Generating Revenue
5. Accelerator/Incubator 16-Dec-2021 Completed Generating Revenue
4. Accelerator/Incubator 27-Oct-2021 $1.16M $1.17M Completed Generating Revenue
3. Accelerator/Incubator 08-Jul-2021 $10K Completed Generating Revenue
To view Apeikon Therapeutics’s complete valuation and funding history, request access »

Apeikon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary A
To view Apeikon Therapeutics’s complete cap table history, request access »

Apeikon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of activatable nanoparticles designed for targeted drug delivery in hard-to-treat tumors. The company serves c
Drug Delivery
London, United Kingdom
3 As of 2026

Planegg, Germany
 

Oslo, Norway
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Apeikon Therapeutics Competitors (3)

One of Apeikon Therapeutics’s 3 competitors is Thermosome, a Venture Capital-Backed company based in Planegg, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Thermosome Venture Capital-Backed Planegg, Germany
EXACT Therapeutics Formerly VC-backed Oslo, Norway
OxSonics Therapeutics Venture Capital-Backed Oxford, United Kingdom
You’re viewing 3 of 3 competitors. Get the full list »

Apeikon Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apeikon Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
KCP Nominees Corporation Minority
SFC Capital Venture Capital Minority
Science Entrepreneur Club Accelerator/Incubator
Change Makers Accelerator/Incubator
King's20 Accelerator Accelerator/Incubator Minority
You’re viewing 5 of 10 investors. Get the full list »

Apeikon Therapeutics FAQs

  • When was Apeikon Therapeutics founded?

    Apeikon Therapeutics was founded in 2020.

  • Where is Apeikon Therapeutics headquartered?

    Apeikon Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Apeikon Therapeutics?

    Apeikon Therapeutics has 3 total employees.

  • What industry is Apeikon Therapeutics in?

    Apeikon Therapeutics’s primary industry is Drug Delivery.

  • Is Apeikon Therapeutics a private or public company?

    Apeikon Therapeutics is a Private company.

  • What is the current valuation of Apeikon Therapeutics?

    The current valuation of Apeikon Therapeutics is .

  • What is Apeikon Therapeutics’s current revenue?

    The current revenue for Apeikon Therapeutics is .

  • How much funding has Apeikon Therapeutics raised over time?

    Apeikon Therapeutics has raised $1.35M.

  • Who are Apeikon Therapeutics’s investors?

    KCP Nominees, SFC Capital, Science Entrepreneur Club, Change Makers, and King's20 Accelerator are 5 of 10 investors who have invested in Apeikon Therapeutics.

  • Who are Apeikon Therapeutics’s competitors?

    Thermosome, EXACT Therapeutics, and OxSonics Therapeutics are competitors of Apeikon Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process